Published in Chest on April 01, 2015
The stats are in: an update on statin use in COPD. Int J Chron Obstruct Pulmon Dis (2015) 0.78
N-acetylcysteine in COPD: why, how, and when? Multidiscip Respir Med (2016) 0.76
Review: Cannabinoids may improve symptoms for some indications but increase adverse events. Ann Intern Med (2015) 0.75
Review: Influenza vaccination and inhaled therapies prevent acute exacerbations in COPD. Ann Intern Med (2015) 0.75
Prompt initiation of maintenance treatment following a COPD exacerbation: outcomes in a large insured population. Int J Chron Obstruct Pulmon Dis (2016) 0.75
The impact of pharmacist-managed clinic on medication adherence and health-related quality of life in patients with COPD: a randomized controlled study. Patient Prefer Adherence (2016) 0.75
Pharmacological Management and Prevention Of Exacerbations of Chronic Obstructive Pulmonary Disease in Hospitalized Patients. P T (2016) 0.75
Long-term safety of tiotropium delivered by Respimat(®) SoftMist™ Inhaler: patient selection and special considerations. Ther Clin Risk Manag (2016) 0.75
Hospital readmissions for COPD: a retrospective longitudinal study. NPJ Prim Care Respir Med (2017) 0.75
Effectiveness of a pharmacist-driven intervention in COPD (EPIC): study protocol for a randomized controlled trial. Trials (2016) 0.75
Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases. J Thorac Dis (2017) 0.75
COPD exacerbation care bundle improves standard of care, length of stay, and readmission rates. Int J Chron Obstruct Pulmon Dis (2016) 0.75
A case report of QT prolongation with glycopyrronium bromide in a patient with chronic tamoxifen use. BMC Res Notes (2016) 0.75
Optimizing bronchodilation in the prevention of COPD exacerbations. Respir Res (2017) 0.75
Current and Emerging Uses of Statins in Clinical Therapeutics: A Review. Lipid Insights (2016) 0.75
Appropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawal. NPJ Prim Care Respir Med (2016) 0.75
Mucoactive and antioxidant medicines for COPD: consensus of a group of Chinese pulmonary physicians. Int J Chron Obstruct Pulmon Dis (2017) 0.75
Four patients with a history of acute exacerbations of COPD: implementing the CHEST/Canadian Thoracic Society guidelines for preventing exacerbations. NPJ Prim Care Respir Med (2015) 0.75
Sex and gender considerations in Canadian clinical practice guidelines: a systematic review. CMAJ Open (2017) 0.75
Effects of Low-Dose and Long-Term Treatment with Erythromycin on Interleukin-17 and Interleukin-23 in Peripheral Blood and Induced Sputum in Patients with Stable Chronic Obstructive Pulmonary Disease. Mediators Inflamm (2016) 0.75
Self-management behaviors to reduce exacerbation impact in COPD patients: a Delphi study. Int J Chron Obstruct Pulmon Dis (2017) 0.75
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2007) 47.86
Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ (2008) 41.81
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
Improving primary care for patients with chronic illness. JAMA (2002) 21.19
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med (2007) 19.86
Improving primary care for patients with chronic illness: the chronic care model, Part 2. JAMA (2002) 19.28
Lost in knowledge translation: time for a map? J Contin Educ Health Prof (2006) 18.58
The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health (1998) 17.71
A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med (2008) 17.19
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J (2004) 16.84
Chronic disease management: what will it take to improve care for chronic illness? Eff Clin Pract (1999) 16.57
The natural history of chronic airflow obstruction. Br Med J (1977) 13.04
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2003) 10.97
Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep (2010) 10.59
Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA (1994) 10.46
Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 10.05
GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol (2011) 10.02
AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ (2010) 8.73
Azithromycin for prevention of exacerbations of COPD. N Engl J Med (2011) 8.66
Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med (2011) 7.92
New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med (2002) 7.87
Chronic obstructive pulmonary disease surveillance--United States, 1971-2000. MMWR Surveill Summ (2002) 7.07
Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med (2003) 6.82
Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med (2013) 6.36
Effect of telehealth on use of secondary care and mortality: findings from the Whole System Demonstrator cluster randomised trial. BMJ (2012) 5.87
Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) Am J Respir Crit Care Med (1996) 5.82
Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J (2003) 5.53
Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med (2007) 5.51
Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med (2003) 5.12
Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest (2007) 5.01
Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med (2005) 4.95
Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2006) 4.80
Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest (2006) 4.77
Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med (1999) 4.66
Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet (1996) 4.65
Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J (2013) 4.65
An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med (2013) 4.49
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet (2009) 4.40
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet (2009) 4.29
Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J (2007) 4.27
Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax (2002) 4.26
Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med (2013) 4.22
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J (2003) 4.20
Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med (2006) 4.11
A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann Intern Med (2012) 4.10
Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet (2001) 3.96
Toward a consensus definition for COPD exacerbations. Chest (2000) 3.70
Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care. Can Respir J (2008) 3.67
Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet (2008) 3.62
Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med (2014) 3.51
Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med (2012) 3.51
Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med (2000) 3.43
Efficacy of salmeterol xinafoate in the treatment of COPD. Chest (1999) 3.38
Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J (2004) 3.19
Deaths: final data for 2009. Natl Vital Stat Rep (2011) 3.18
Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med (2014) 3.11
The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest (2003) 3.09
Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax (1999) 3.00
Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2002) 2.99
Integrated care prevents hospitalisations for exacerbations in COPD patients. Eur Respir J (2006) 2.93
Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med (2013) 2.92
Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet (1999) 2.90
Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2001) 2.83
A taxonomy for disease management: a scientific statement from the American Heart Association Disease Management Taxonomy Writing Group. Circulation (2006) 2.81
Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med (2013) 2.75
Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med (2008) 2.66
Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med (2010) 2.60
Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep (2010) 2.52
Twenty years of telemedicine in chronic disease management--an evidence synthesis. J Telemed Telecare (2012) 2.40
Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis (1983) 2.38
Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2011) 2.38
Statin use and risk of COPD exacerbation requiring hospitalization. Am J Med (2013) 2.29
Integrated disease management interventions for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2013) 2.23
Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2012) 2.21
The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. Respir Med (2007) 2.09
Telehealthcare for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2011) 2.02
Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration (2010) 2.00
Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J (2004) 1.98
Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2012) 1.95
Economic analysis of the Confronting COPD survey: an overview of results. Respir Med (2003) 1.93
Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol (2006) 1.92
Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol (2006) 1.91
Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest (2003) 1.90
Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest (2004) 1.89
Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med (2008) 1.89
Telemedicine experience for chronic care in COPD. IEEE Trans Inf Technol Biomed (2006) 1.89
Glucocorticosteroids: current and future directions. Br J Pharmacol (2011) 1.85
Using preventive home monitoring to reduce hospital admission rates and reduce costs: a case study of telehealth among chronic obstructive pulmonary disease patients. J Telemed Telecare (2012) 1.83
Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest (2002) 1.83
Effect of an action plan with ongoing support by a case manager on exacerbation-related outcome in patients with COPD: a multicentre randomised controlled trial. Thorax (2011) 1.82
Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest (1996) 1.82
Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax (2007) 1.81
Outpatient pulmonary rehabilitation following acute exacerbations of COPD. Thorax (2010) 1.79
Azithromycin for prevention of exacerbations of COPD. N Engl J Med (2011) 8.66
Lebrikizumab treatment in adults with asthma. N Engl J Med (2011) 8.07
A randomized study of endobronchial valves for advanced emphysema. N Engl J Med (2010) 6.23
American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med (2006) 5.65
Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med (2012) 5.54
Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med (2007) 5.51
An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med (2013) 4.49
Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J (2007) 4.27
Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19
Effects of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med (2008) 4.12
A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann Intern Med (2012) 4.10
A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med (2016) 3.99
An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med (2008) 3.98
GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med (2012) 3.98
The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 3.85
Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care. Can Respir J (2008) 3.67
An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med (2012) 3.62
Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2009) 3.61
Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med (2014) 3.51
Evidence for improving palliative care at the end of life: a systematic review. Ann Intern Med (2008) 3.48
Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology (2011) 3.30
Overdiagnosis of asthma in obese and nonobese adults. CMAJ (2008) 3.23
Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease--2003. Can Respir J (2003) 3.14
Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA (2004) 3.07
Lung cancer in patients with chronic obstructive pulmonary disease-- incidence and predicting factors. Am J Respir Crit Care Med (2011) 2.93
Point: should we abandon FEV₁/FVC <0.70 to detect airway obstruction? No. Chest (2010) 2.89
Counterpoint: Exercise-induced intrapulmonary shunting is real. J Appl Physiol (1985) (2009) 2.88
Comparison of spirometric thresholds in diagnosing smoking-related airflow obstruction. Thorax (2013) 2.88
Sex differences in severe pulmonary emphysema. Am J Respir Crit Care Med (2007) 2.77
Gender and COPD in patients attending a pulmonary clinic. Chest (2005) 2.59
Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg (2006) 2.53
Seeking worldwide professional consensus on the principles of end-of-life care for the critically ill. The Consensus for Worldwide End-of-Life Practice for Patients in Intensive Care Units (WELPICUS) study. Am J Respir Crit Care Med (2014) 2.46
Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest (2008) 2.37
Clinical practice guideline: hoarseness (dysphonia). Otolaryngol Head Neck Surg (2009) 2.31
Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: a pilot study. Respir Med (2013) 2.24
Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc (2008) 2.20
Multicomponent indices to predict survival in COPD: the COCOMICS study. Eur Respir J (2012) 2.18
Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest (2005) 2.15
Relationship between quantitative CT metrics and health status and BODE in chronic obstructive pulmonary disease. Thorax (2012) 2.15
The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. Am J Respir Crit Care Med (2011) 2.15
Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med (2010) 2.09
Incidence and risk factors for venous thromboembolic disease in podiatric surgery. Chest (2008) 2.09
An official American Thoracic Society workshop report: assessment and palliative management of dyspnea crisis. Ann Am Thorac Soc (2013) 2.08
Self-management programmes for COPD: moving forward. Chron Respir Dis (2012) 2.07
A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation. COPD (2012) 2.07
Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med (2007) 2.04
Six-minute walk distance in chronic obstructive pulmonary disease: reproducibility and effect of walking course layout and length. Am J Respir Crit Care Med (2003) 2.03
Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 2.02
Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. Respir Care (2006) 2.00
C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest (2008) 1.98
Infant feeding tube as rescue endotracheal tube in an infant with an aerodigestive foreign body. J Anesth (2013) 1.98
Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function. Am J Respir Crit Care Med (2013) 1.93
Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. Am J Respir Crit Care Med (2008) 1.90
Bronchodilator reversibility in COPD. Chest (2011) 1.89
Arterial oxygenation influences central motor output and exercise performance via effects on peripheral locomotor muscle fatigue in humans. J Physiol (2006) 1.88
Quantifying the extent of emphysema: factors associated with radiologists' estimations and quantitative indices of emphysema severity using the ECLIPSE cohort. Acad Radiol (2011) 1.88
Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest (2003) 1.86
Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med (2007) 1.85
Effect of an action plan with ongoing support by a case manager on exacerbation-related outcome in patients with COPD: a multicentre randomised controlled trial. Thorax (2011) 1.82
CT metrics of airway disease and emphysema in severe COPD. Chest (2009) 1.81
Interstitial lung abnormalities and reduced exercise capacity. Am J Respir Crit Care Med (2012) 1.80
Overdiagnosis of asthma in the community. Can Respir J (2004) 1.80
A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest (2007) 1.79
A cohort study showed that health insurance databases were accurate to distinguish chronic obstructive pulmonary disease from asthma and classify disease severity. J Clin Epidemiol (2005) 1.76
Treatment of persistent pulmonary air leaks using endobronchial valves. Chest (2009) 1.75
Advanced chronic obstructive pulmonary disease: innovative approaches to palliation. J Palliat Med (2007) 1.74
Pneumothorax following endobronchial valve therapy and its impact on clinical outcomes in severe emphysema. Respiration (2014) 1.74
Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax (2012) 1.72
A systematic review of satisfaction with care at the end of life. J Am Geriatr Soc (2007) 1.71
Point: Are the CHEST guidelines global in coverage? Yes. Chest (2015) 1.70
Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med (2009) 1.70
The true false negative rates of esophageal and endobronchial ultrasound in the staging of mediastinal lymph nodes in patients with non-small cell lung cancer. Ann Thorac Surg (2010) 1.69
Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med (2014) 1.68
Physician and patient perceptions in COPD: the COPD Resource Network Needs Assessment Survey. Am J Med (2005) 1.67
Respiratory failure after lung transplantation. Chest (2003) 1.67
Gender differences of airway dimensions in anatomically matched sites on CT in smokers. COPD (2011) 1.66
Racial differences in quality of life in patients with COPD. Chest (2011) 1.64
A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease. PLoS One (2012) 1.64
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 1.63
A Canadian, multicentre, randomized clinical trial of home-based pulmonary rehabilitation in chronic obstructive pulmonary disease: rationale and methods. Can Respir J (2005) 1.63